ABSTRACT
and
Vero cells infected
with T cruzi, were exposed to these peptides. The result, in both cases, was a significant eukaryotic cells were unaffected by the treatments. In view of the worldwide prevalence of these protozoan diseases and the lack of completely suitable treatments, lytic peptides may provide new and unique chemotherapeutic agents for the treatment of these infections. has been an important factor in reducing the mortality caused by malaria; however, in many countries, the prevalence of this disease is increasing at a rate of approximately 10 million new cases a year (2). This is due primarily to the development of drug resistance by Plasmodium s/i. and to vector resistance to insecticides (3). Treatment of Chagas' disease has focused on the utilization of purine derivatives (e.g., allopurine), which disrupt normal nucleic acid metabolism (4). However, the deleterious effects of these drugs are not limited to the parasite, but are also toxic to host cells (5). Therefore, the established chemoetherapeutic treatments are less than completely effective or ideal for Shiva-1 was found to be approximately twice as effective (on a tM basis) as SB-37 in limiting the growth of the parasites (Fig. 3) . The peptides caused no significant increase in lysis of either uninfected or infected erythrocytes (data not shown). are currently under way and should provide information on how the lytic effects are exerted.
